Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Clinical and sociodemographic features of Puerto Ricans with systemic sclerosis.

Ríos G, Mayor AM.

Ethn Dis. 2010 Winter;20(1 Suppl 1):S1-185-9.

PMID:
20521412
2.

Clinical manifestations of systemic sclerosis.

Steen VD.

Semin Cutan Med Surg. 1998 Mar;17(1):48-54. Review.

PMID:
9512107
3.

Systemic sclerosis/scleroderma: a treatable multisystem disease.

Hinchcliff M, Varga J.

Am Fam Physician. 2008 Oct 15;78(8):961-8.

4.

Clinical and demographic predictors of loss of pulmonary function in systemic sclerosis.

Peters-Golden M, Wise RA, Schneider P, Hochberg M, Stevens MB, Wigley F.

Medicine (Baltimore). 1984 Jul;63(4):221-31.

PMID:
6738343
5.

Evolution of primary Raynaud's phenomenon (Raynaud's disease) to connective tissue disease.

Gerbracht DD, Steen VD, Ziegler GL, Medsger TA Jr, Rodnan GP.

Arthritis Rheum. 1985 Jan;28(1):87-92.

PMID:
3871330
6.

Prospective, open-label, uncontrolled pilot study to study safety and efficacy of sildenafil in systemic sclerosis-related pulmonary artery hypertension and cutaneous vascular complications.

Kumar U, Sankalp G, Sreenivas V, Kaur S, Misra D.

Rheumatol Int. 2013 Apr;33(4):1047-52. doi: 10.1007/s00296-012-2466-5. Epub 2012 Jul 26. Erratum in: Rheumatol Int. 2013 Apr;33(4):1053. Gokhle, Sankalp S [corrected to Sankalp, Gokhale].

PMID:
22833239
7.

Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years.

Bettoni L, Geri A, Airò P, Danieli E, Cavazzana I, Antonioli C, Chiesa L, Franceschini F, Grottolo A, Zambruni A, Radaeli E, Cattaneo R.

Clin Rheumatol. 2002 Jun;21(3):244-50.

PMID:
12111631
8.

Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study.

Kawald A, Burmester GR, Huscher D, Sunderkötter C, Riemekasten G.

J Rheumatol. 2008 Sep;35(9):1830-7. Epub 2008 Jul 15.

PMID:
18634152
9.

Evidence for oesophageal and anorectal involvement in very early systemic sclerosis (VEDOSS): report from a single VEDOSS/EUSTAR centre.

Lepri G, Guiducci S, Bellando-Randone S, Giani I, Bruni C, Blagojevic J, Carnesecchi G, Radicati A, Pucciani F, Marco MC.

Ann Rheum Dis. 2015 Jan;74(1):124-8. doi: 10.1136/annrheumdis-2013-203889. Epub 2013 Oct 15.

PMID:
24130266
10.

Digital ulcers and cutaneous subsets of systemic sclerosis: Clinical, immunological, nailfold capillaroscopy, and survival differences in the Spanish RESCLE Registry.

Tolosa-Vilella C, Morera-Morales ML, Simeón-Aznar CP, Marí-Alfonso B, Colunga-Arguelles D, Callejas Rubio JL, Rubio-Rivas M, Freire-Dapena M, Guillén-Del Castillo A, Iniesta-Arandia N, Castillo-Palma MJ, Egurbide-Arberas M, Trapiellla-Martínez L, Vargas-Hitos JA, Todolí-Parra JA, Rodriguez-Carballeira M, Marin-Ballvé A, Pla-Salas X, Rios-Blanco JJ, Fonollosa-Pla V; RESCLE Investigators, Autoimmune Diseases Study Group (GEAS).

Semin Arthritis Rheum. 2016 Oct;46(2):200-8. doi: 10.1016/j.semarthrit.2016.04.007. Epub 2016 May 18.

PMID:
27312381
11.

Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study.

Jaeger VK, Wirz EG, Allanore Y, Rossbach P, Riemekasten G, Hachulla E, Distler O, Airò P, Carreira PE, Balbir Gurman A, Tikly M, Vettori S, Damjanov N, Müller-Ladner U, Distler JH, Li M, Walker UA; EUSTAR co-authors.

PLoS One. 2016 Oct 5;11(10):e0163894. doi: 10.1371/journal.pone.0163894. eCollection 2016.

12.

Prevalence and evolution of scleroderma pattern at nailfold videocapillaroscopy in systemic sclerosis patients: Clinical and prognostic implications.

Ghizzoni C, Sebastiani M, Manfredi A, Campomori F, Colaci M, Giuggioli D, Ferri C.

Microvasc Res. 2015 May;99:92-5. doi: 10.1016/j.mvr.2015.03.005. Epub 2015 Apr 2.

PMID:
25842153
13.

[How to recognize scleroderma].

Francès C, Ayoub N, Barete S.

Rev Prat. 2002 Nov 1;52(17):1884-90. Review. French.

PMID:
12532864
14.

Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients.

Poormoghim H, Lucas M, Fertig N, Medsger TA Jr.

Arthritis Rheum. 2000 Feb;43(2):444-51.

15.

Profile of systemic sclerosis in a tertiary care center in North India.

Sharma VK, Trilokraj T, Khaitan BK, Krishna SM.

Indian J Dermatol Venereol Leprol. 2006 Nov-Dec;72(6):416-20.

16.

[Autoantibodies in systemic sclerosis and their clinical correlation in patients from a Midwestern region of Brazil].

Coelho Horimoto AM, da Costa IP.

Rev Bras Reumatol. 2015 May-Jun;55(3):229-39. doi: 10.1016/j.rbr.2014.09.007. Epub 2014 Nov 7. Portuguese.

17.

[Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].

Serri J, Legré R, Veit V, Guardia C, Gay AM.

Ann Chir Plast Esthet. 2013 Dec;58(6):658-62. doi: 10.1016/j.anplas.2011.11.001. Epub 2011 Dec 26. French.

PMID:
22204894
18.

Progressive systemic sclerosis sine scleroderma in a child presenting as nocturnal seizures and Raynaud's phenomenon.

Navon P, Halevi A, Brand A, Branski D, Rubinow A.

Acta Paediatr. 1993 Jan;82(1):122-3.

PMID:
8453211
19.

[Clinical features of systemic sclerosis and association with antitopoisomerase-1 antibody and centromere pattern of antinuclear antibody].

Bertazzi GR, de Toledo RA, de Godoy MF, Geraldino GC, Polizelli DV, Fernandes GC, Pedroso CL, dos Santos FG, de Assis TM.

Acta Reumatol Port. 2012 Jan-Mar;37(1):9-17. Portuguese.

20.

Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis.

Minier T, Guiducci S, Bellando-Randone S, Bruni C, Lepri G, Czirják L, Distler O, Walker UA, Fransen J, Allanore Y, Denton C, Cutolo M, Tyndall A, Müller-Ladner U, Matucci-Cerinic M; EUSTAR co-workers; EUSTAR co-workers.

Ann Rheum Dis. 2014 Dec;73(12):2087-93. doi: 10.1136/annrheumdis-2013-203716. Epub 2013 Aug 12.

PMID:
23940211

Supplemental Content

Support Center